image loadingimage loading
Bob Lanier


Text Box:  Dr. Bobby Lanier was the 98th president to the Tarrant County Medical Society.  He is also Past President of the American College of Allergy Asthma and Immunology and distinguished fellow, and Past president of the Association of Certified Allergists, and the Texas Medical Association Foundation.  Dr. Lanier is Board Certified by the American Board of Pediatrics, the Conjoint Board of Medicine and Pediatrics of Allergy Immunology, and the  American Academy of Pharmaceutical Physicians and Association of Certified Research Professionals. Dr. Lanier serves on The Emerging  Medical Societies taskforce and the Board of Directors for the World Allergy Association and travels extensively in that capacity.     Dr. Lanier is a Clinical Professor at the University of North Texas Health Science Center, Texas College of Osteopathic Medicine.  He has authored over 60 original contributions to the medical literature in peer reviewed journals, has written 2 textbook chapters in allergy and is active in the cutting edge of respiratory research through his firm North Texas Institute for Clinical Trials, being best known for his work on monoclonal anti-IgE.  He has given over 100 presentations for Medical grand rounds in universities in this country, Europe, Asia, Australia, and South America in the last three years and is widely known for his dynamic, technologically advanced,  and entertaining style.  

 

Dr. Lanier and his wife Sandy and their two children arrived in Fort Worth in 1977 with the completion of military service.  Together they have worked to the benefit of people with AIDS and other community efforts. Dr. Lanier is the son of a union organizer and a school teacher who grew up in the refinery towns of south east Texas.  He experienced an extended childhood illness causing him to spend several years at John Sealy Hospital in Galveston where he would later attend medical school.  Home schooled because of his illness, Dr. Lanier attended public school full time first in the seventh grade, and eventually graduated as a co-valedictorian.   Dr. Lanier worked as a laboratory technician from high school through residency.  He attended Lamar University in Beaumont where he was recognized as a distinguished graduate, and the University of Texas Medical Branch in Galveston where he received his MD degree.

After a pediatric internship at UTMB, Dr. Lanier served in the Air Force and completed a Pediatric Residency at Wilford Hall USAF Medical Center in San Antonio.  He then was granted a civilian fellowship in Clinical Immunology at the Shrine Burns Institute in Galveston.   He returned to the Air Force to help set up the first training program in allergy and immunology where he continued until moving to Fort Worth in 1977.

Dr. Lanier founded Fort Worth Allergy and Asthma Associates in 1977 and continues in active practice at North Texas Institute for Clinical trials.   He sustains a practice for the indigent and non-insured community and as medical director of Lanier Education and Research Network, a corporation devoted to educational technology and pharmaceutical research.  Dr. Lanier founded the Society of Principal Investors, a professional society of physicians conducting FDA pharmaceutical trials. Since joining the medical society in 1977, Dr. Lanier has been involved intensely in communication efforts.  A medical society committee assignment in 1980 led to his involvement locally with the NBC television affiliate where he served in a public service capacity from 1981-2001. He has appeared on “Ophra”, several times on “Nightline with Ted Koppell”, the “Today Show ”,”Nightly News with Tom Brohaw”,  “Good Morning America”, “Good Morning South Africa” and “Radio Zulu”.   Dr. Lanier founded the National Association of Physician Broadcasters.   Dr. Lanier also served as an NBC television network correspondent from 1982-1985 after which time his television segments were internationally syndicated daily to over 100 television markets and heard in over 250 radio stations in this country and worldwide through the Armed Forces Radio and Television Network.  Dr. Lanier founded the National Association of Physician Broadcasters.  He was honored in 1995 by the American Text Box:  Medical Association with the Education and Research Foundations award for public communications.

Dr. Lanier stood for public office ( Congressional District 12) in 1989 and was defeated by Rep. Pete Geren .  Dr. Lanier co-chaired the successful Congressional campaign of Representative Kay Granger.

Dr. Lanier is a passionate fisherman, photographer, and sports writer .His articles and photographs have appeared in in-flight and sports magazines.   He has written over 400 articles on sports fishing for magazines such as Saltwater Sportsman, Texas Parks and Wildlife and American Sportsman.   Dr. Lanier is also a computer programmer and currently served as a consultant for the American Medical Association for website development and computer related ethical issues.  His hobby is technology – he is a die hard gadgeteer.

 

BOBBY QUENTIN LANIER, M.D.

6407 Southwest Boulevard    Fort Worth, Texas 76132

 

 

CURRICULUM VITAE

Texas State Board of Medical Examiners                                                         Revised 10-2-2007

 

 

EDUCATION

 

·         Undergraduate education: Lamar University (B.S. Biology, 1966)

·         Professional education: University of Texas Medical Branch (M.D., 1966-1970)

·         Post-graduate professional education:

            Internship - University of Texas Medical Branch at Galveston

                                (Pediatrics, 1970-1971)  

            Residency - Wilford Hall USAF Medical Center

                                (Pediatrics, 1971-1973) Certification, 1975

            Fellowship:  University of Texas Medical Branch at Galveston

                                (Immunology 1973-1975) Certification, (1977)

·         Certified Clinical Research Investigator: Association of Clinical Research Professionals (2002)

·         Certified Clinical Research Investigator: Academy of Pharmaceutical Physicians (2004)

 

AWARDS

 

·         Achievement Award, American Lung Association of Texas (2002)

·         Bela Schick Lecture, American College of Allergy Asthma and Immunology 1996

·         Distinguished Fellow, American College of Allergy Asthma and Immunology 1995

·         American Medical Association, Education and Research Foundation Award

For Health Education (1994)

·         Distinguished Alumni Lamar University (1994)

·         Heart Association Paul R. Ellis Media Award  (1990, 1994, 1998)

·         Tarrant County Medical Association, Community Service Award (1987)

·         Best Documentary “Cancer:  Texas Strikes Back” Texas Cancer Society,(1987)

·         Achievement of Excellence, documentary “Cancer:  Texas Strikes Back” 

      Dallas Press Club (1987)

 

·         American Academy of Family Physicians Active Teacher Award

      (1980, 1981, 1982, 1983, 1984, 1985, 1986)

 

PROFESSIONAL EXPERIENCE

 

·         Clinical Professor of Pediatrics: University of North Texas Health Science Center (present)

·         Editorial Board Proceedings of Allergy Asthma and Immunology (2004 – present)

·         Editor - American College of Allergy, Asthma and Immunology Symposia (2002)

·         Editor – John Hopkins, Asthma Monitor (2001-2002)

·         Medical Director- North Texas Institute for Clinical Trials: (1982-present)

·         Founder and Executive Director- Medical Media Network: (1982-present)

·         Private Practice- (1977- 1999)

·         Founder: Fort Worth Allergy and Asthma Associates (1977)

·         Chief / training director - Ped Allergy/Immunology, Wilford Hall USAF

      Medical Center San Antonio, Texas (1975- 1977)

 

EXECUTIVE POSITIONS HELD

 

·         Board of Directors, World Allergy Organization (2005- present)

·         President – Association of Certified Allergists (2002-2003)

·         President - American College of Allergy Asthma and Immunology (2001 – 2002)

·         President: Texas Medical Association Foundation (2001- 2003)

·         President: Tarrant County Medical Society (2000)

·         Founder/EVP: Society of Principal Investigators (2000 – present)

·         Board of Directors; Texas Medical Association Foundation (1998-present)

·         Chairman: AllerDays Research Council for HMR  (1997-1999) 

·         Chairman: Managed Care Council: American College of Allergy Asthma

       and Immunology (1995-1996)

·         President: Fort Worth Academy of Medicine ( 1994-1996)

·         Treasurer: Tarrant County Medical Society ( 1994-1995)

·         Founder and Executive Director: Academy of Radio and Television Health

      Communicators (1990- present)

·         Delegate (alt) American Medical Association American College of Allergy Asthma

      and Immunology (1990-present)

·         Board of Directors: Joint Council of Allergy and Immunology (1990-1995)

·         Senior Vice President Harris Methodist Health System, Communications

      Research (1989- 1998)

·         Anchor / Editor:  Medical Economics Video Magazine (1989 - 1995)

·         Board of Regents, Executive Committee, American College Allergy and

       Immunology (1989- 1995)

·         Chairman: International Allergy Group for Scherring Corporation (1989-1993)

·         President, National Association of Physician Broadcasters (1989-1991)

·         Nominee for Congress, District 12  (1989)

·         Chairman, Joint Marketing Task Force, American College Allergy and

      Immunology (1987-1990)

·         Chairman, Public Education Task Force on Cancer (1987)

·         Founder, National Association of Physician Broadcasters (1986-1991)

·         Medical Consultant, NBC News (1984-1986)

·         Co-Chairman, Texas Legislative Task Force on Cancer (1984-1986)

·         Chairman, Council on Communications, Texas Medical

      Association (1984-1985)

·         Medical Director, North Texas Institute for Clinical Trials, Fort Worth, Texas

      (1982-Present)

·         Founder/CEO - Bob Lanier, MultiMedia - (1982 - present) A medical communications and video corporation

·         Medical Consultant, KXAS TV, (NBC) (1981 - 1998)

 

 

PROFESSIONAL ORGANIZATIONS

     

·         World Allergy Organization (2001 – present)

·         American Academy of General Physicians (1997-present)

·         Alternate Delegate (American College of Allergy Asthma and Immunology)

       American Medical Assoc.,  (1991- present)

·         Society of Professional Journalists (1988-present)

·         Radio & Television News Directors Association (1987-present)

·         Board of Directors, American Lung Association (1984-1985)

·         Tarrant County Medical Communication and Public Relations Committee (1981-1985)

·         American Medical Association (1979-present)

·         Texas Medical Association (1979-present)

·         Tarrant County Pediatric Society (1979-present)

·         Fellow, American College of Allergists (1979-present)  

·         Board of Directors, Tarrant County Medical Society (1979-1985)

·         Board of Directors, Fort Worth Academy of Medicine (1978-1985)

·         American Association of Certified Allergists (1977-present)

·         Fellow, American Academy of Pediatrics (1977-present)

·         Diplomat, American Board of Pediatrics (1975-present)

·         Phi Beta Phi Medical Fraternity (1966-present)

 

TEACHING POSITIONS

   

·         Clinical Professor of Pediatrics: University of North Texas Health Science Center (2003-2006)

·         Faculty: Pilot program Scientific Communications fellowship World Allergy Organization (2006)

·         Assistant Clinical Professor, Department of Medicine University of Texas Health

Science Center, Dallas TX - UTHSC Dallas (1979-2001)

·         Faculty, American Medical Association - Annual Health Reporting

      Conference (1982-1990)

·         Supervisor: Clerkships for Family Practice Residents, John Peter Smith Hospital

      Fort Worth, Texas (1980- 1988)

·         Director Allergy division:  Department of Family Practice, John Peter Smith Hospital,

      Fort Worth, Texas (1979-1985)

·         Attending physician:  Division of Internal Medicine and Family Practice, Wilford Hall USAF Medical Center, San Antonio, Texas  (1975-1977)

 

COMMUNITY ORGANIZATIONS

 

·         Advisory Board of Directors, Samaritan Housing for AIDS (1997-present)

·         Advisory Board, Tarrant County Harvest (1991- 1995)

·         Advisory Board of Directors, AIDS Outreach Center (1990-present)   

·         Advisory Board Member, American Institute for Teen AIDS Prevention (1990-present)

·         Spokesperson, Kid Care - Volunteer Connection, KXAS-TV  (1990-1998)

·         Finance and Executive Board, First United Methodist Church,

      Fort Worth (1990- 1994)

·         Board of Directors: Women with Aids (a childcare facility for the children of

      families with AIDS)  (1988)

·         Board of Directors: University Place (Elderly Retirement Center and

      Medical Facility) (1984-1998)

·         Board of Directors, Salvation Army (1983-1987)

·         Founder, Asthma Camp for Children, "Camp Huff 'n Puff" (1982-present)

·         Board of Directors, Citizens Advisory Council for Cable Television (1981-1983)

·         Board of Directors, Camp Carter-YMCA (1981-1983)

 

MEDIA EXPERIENCE

 

·         Oprah, 1999, “Surviving a Hospital Stay”

·         Talent: Schering Cable television half hour : Allergies - fact and myth ( 1995)

·         Talent: Schering Cable television half hour:  Allergies- how to survive (1995)

·         Talent: "Medical Talk Etc..."  KCBI Radio - weekly medical talk show (1991- 1993)

·         Medical reporter - KCBI Radio (1990-present)

·         Anchor:  Medical Economics Video Magazine, a quarterly broadcast

      and tape (1989-1995)

·         Medical commentator - WBAP Radio (1985-2001)

·         Talent, Writer, Producer: Sixty Second Housecall, daily national radio/television commentary in syndication  (1985- 2001) 

·         Nightline Guest (ABC), Jan. 1985, "The Fate of Private Practice".

·         Medical Reporter, KXAS TV, (NBC) (1981 - Present)

·         NBC "A" News correspondent (1984-1986)

·         Medical commentator - "Master Control", Southern Baptist Radio/TV

Commission (1984-1986)

·         Nightline Guest (ABC), July 1984, "Controversies in Allergy".

·         Medical commentator: Medical Portfolio - an audio cassette journal (1983-present)

·         Talent, producer, writer: Glaxo- “Overview of Allergy  (Introductory videotape)

·         Talent, writer, producer: Glaxo- “Overview of Asthma  (Introductory videotape)

·         Talent, writer, producer: “Good news about heart attack treatment” 30 minute

       broadcast documentary (1990)

 

BOOKS

 

·         Textbook Chapter, Anti-IgE “Atlas of Allergy” Blaiss, Liberman 2005

·         The Physician as Communicator - a text of communication skills for physicians.

·         The New Epidemic:  A Patient Survival Guide to Asthma (in progress)

·         CD-ROM: Interactive Cases in Asthma (1995)

·         CD-i  Interactive Asthma Education Series

 

 

 

PUBLICATIONS

 

  • Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH, Lanier BQ, Penna P; Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg. 2007 Jun;136(6 Suppl):S107-24.
  • Lanier B; Allergic rhinitis: selective comparisons of the pharmaceutical options for management.  Allergy Asthma Proc. 2007 Jan-Feb;28(1):16-9. Review.
  • Lanier BQ:  Epinastine 0.05% for the Treatment of Allergic Conjunctivitis, Expert Review of Opthamology, in press
  • Liping, W, Yin,j Lanier,B   Baboon Syndrome Contact Dermatitis 56:356-357, 2007
  • Lanier, Bob Q.  Unanswered questions and speculations about the role of anti-immunologlobulin E in atopic and nonatopic disease , Allergy Asthma Proceedings Vol. 27, No. 2 March-April 2006, Supplement No.1
  • Lanier, Bob Q. Unanswered Questions and Warnings Involving Anti–Immunoglobulin E Therapy Based on 2-Year Observation of Clinical Experience Proceedings of Allergy Asthma and ImmunologyVolume 26, Number 6, November-December 2005 pp. 435-439(5)
  • Lanier BQ, Abstract:  Anaphylaxis with SIT while being treated with Xolair European Academy of Allergology and Clinical Immunology June 2005 Munich
  • Lanier BQ, Abstract: " IgE does not consistently rise with anti-IgE therapy" presented at ACAAI annual meeting 2005 Nov 2005, Anaheim.
  • Lanier BQ, Abstract: " IgE does not protect against anaphylaxis with SIT" presented at ACAAI annual meeting 2005 Nov.2005,  Anaheim.
  • Lanier BQ, Abstract: " Safety and Efficacy of Olepatidine .6% Nasal spral in Perienial allergic rhinitis" presented at AAAAI annual meeting 2006, March 2006 Miami
  • Lanier BQ, Allergy- On The Rise and in the News, Refractive Eyecare  Feb 2006 V10 Number 2
  • Lanier BQ, Hampel F, Kittner B, Varghese ST, Safety Of Fexofenadine In Pre-School Children With Allergic Rhinitis, Abstract, American Academy of Pediatics, 2005 National Confernece and Exhibition  October 2005, Washington, D.C.
  • BQ Lanier, Editorial Board: Allergy and Asthma Proceedings, (under academic appointments)
  • G.Shapiro, G. Bensch R. Lanier, L. Sher M. Lloyd, S. Kundu, J. Williams, D. Banerji, Once-daily treatment with ciclesonide is effective and well tolerated in children with persistent asthma, Abstract, annual meeting AAAAI, 2005 San Antonio, Texas
  • Lanier BQ, Miller D, Omalizumab is well tolerated in adolescent/adult patients(>=12 years) with moderate-to-severe persistent asthma, Abstract presented at ATS Meeting, May 2005
  • Lanier BQ, Casale TB, Omalizumab is well tolerated in adolescent/adult patients(>=12 years) with moderate-to-severe persistent asthma, Abstract presented at AAAI Annual Meeting, March 2005
  • Lanier BQ, textbook chapter, Blaiss Atlas of Allergy and Immunology – in press
  • Lanier BQ, textbook chapter, Leiberman and Anderson, Allergy and Immunology – in press

 

  • Lanier BQ, Chang TW, Will Anti-IgE therapt Comprimise Normal Immune Functions?, Allergy & Clinical Immunology International, Nov/Dec 2004
  • Lanier BQ, Carr W, Omalizumab in the Treatment of Allergy and Asthma, Drug profile, Therapy 2004 1(1)25-30
  • Lanier BQ, Finegold I, D’Arienzo PA, Clinical Effecacy of Olopatadine vs epinsatine ophthalmic solution in the conjunctival allergen challenge Model, Current Medical Research, Aug 2004
  • Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.J Allergy Clin Immunol. 2004 May;113(5):832-6.
  • Lanier, BQ, Marshall GD Jr, Unanswered questions on Omalzumab (Xolair) patient Selection and Follow-up, Ann Allergy Asthma Immunol, Feb 2004
  • Lanier, BQ, Analysis of the Efficacy of Technical Presentations As a Means of Sharing Data and Modifying Behavior of Professionals, Xolair Source, Jan 2004
  • Roland PS, Kreisler LS, Reese B, Anon JB, Lanier BQ, et al, Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through tympanostomy tubes.Pediatrics. 2004 Jan;113(1 Pt 1)
  • Lanier BQ, Patient education doesn’t work-“edu-tainment” does, Annals of Allergy

Aug 2003

  • Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor AR, Gupta N, Omalizumab is Effective in the Long-Term Control of Severe Allergic Asthma, Annals of Allergy

Aug 2003

  • Lanier, BQ, Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE, Ann Allergy Asthma Immunol. 2003 Jun;90(6 Suppl 3):13-5. Review.
  • Lanier BQ, Ableson MB, Berger WE, Granet DB, D’Arienzo PA, Spanlger DL, Kagi MK, Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge, Clinical Therapeutics, Jul 2002
  • Finegold I, Lanier BQ, Berger W, Blaiss M, Immunotherapy for asthma, Am J Respir Crit Care Med,  May 2002, 15;165(10):1453-4.
  • Lanier BQ, Anti-IgE in the real world, Editorial, Annals of Allergy, May 2002
  • Lanier BQ, Busse W, Corren J, Liu J, Fowler-Taylor AR, Gupta N, Omalizumab is Effective in the Long-Term Control of Severe Allergic Asthma, Submitted JAMA, 2002
  • Weinstein SF(a), Welch MJ, Lanier BQ, Nayak A, Stampone P, New Beclomethasone Diporionate Extrafine Aerosol is Effective Pediatric Asthma Therapy, Abstract, 58th Annual Meeting of the American Academy of Allergy Asthma and Immunology, New York, USA, March 01-06, 2002
  • Lanier BQ, When the whole is more than the sum of it’s parts, Annals of Allergy, Asthma, and Immunology, Dec 2001; 87(6): 445-6.
  • Busse W, Coren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N, Omalizumab, Anti-IgE Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma, J Allergy Clin Immunol, Aug 2001

108(2):184-90

  • Lanier BQ, No Prescription Needed –No Doctor Either, Annals of Allergy, Asthma & Immunology, Jul 2001, 87 (1) p1-2, editorial
  • Lanier BQ, New Treatments and the Future Role of Immunotherapy: Anti-IgE, Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma & Immunology Jul 2001, 87 (1 suppl 1) p68-9
  • Lanier BQ, Gross R D, Marks B, Cockrum PC, Juniper EF, Olopatadine Ophthalmic Solution Adjunctive to Loratadine Compared to Loratadine Alone in Patients With Active Seasonal Allergic Conjunctivitis Symptoms, Annals of Allergy, Asthma, and Immunology, 2001 Jun; 86(6):641-8. 
  • Lanier BQ, Berger WE, D’Arienzo P,  Granet D,  Comparison of the Safety and Efficacy of the Concomitant Use of Flonase® (Fluticasone propionate 5 mcg/aqueous nasal spray) and Patanol® (olopatadine HCl 0.1% ophthalmic solution) versus Allegra® (Fexofenadine HCl 60 mg capsule and Flonase® (Fluticasone propionate 50 mcg/aqueous nasal spray) versus placebo in subjects with allergic rhinoconjunctivitis in the conjunctival allergen challenge (CAC) model In press, Clinical theraputics
  • Tillinghast J(a), Lanier BQ, Busse W,  Chervinsky P, Ashby M, Fowler-Taylor A, Fick R, Gupta N, Omalizumab Significantly Increases Time to First Asthma Exacerbation Compared with Placebo, XXth Congress of the European Academy of Allenology and Clinical Immunology Berlin, Germany May 09-13 2001
  • Lumry W(a), Berger W, Corren J, Lanier BQ, Busse W, Chervinsky P, Nayak A , Fowler-Taylor A, Fick R, Gupta N, Evidence of the Long-term Safety and Tollerability of Omalizmab from a Large Phase III Study, , XXth Congress of the European Academy of Allenology and Clinical Immunology Berlin, Germany May 09-13 2001
  • Nelson H, Fick R, Fowler-Taylor A, Ashby M, Busse W, Chervinsky P, Lanier BQ, Gupta N, Corren J, Rohane P, Increased Time to First Asthma Exacerbation Seen in Xolair Treated Patients Compared with Placebo, Ann. Allergy Asthma Immunol. 86, No.1 98, 2001
  • Berger W, Nayak A, Fowler-Taylor A, Chervinsky P, Busse W, Lanier BQ, Corren J, Gupta N, Rohane P, Fick R, Long-term Safety and Tolerability of Xolair–A Double Blind, Placebo–Controlled Study, Ann. Allergy Asthma Immunol. 886, NO.1 , 97, 2001
  • Lanier BQ, Fowler-Taylor A, gupta W, McAlary M, Corren J, Matz J, Townley R, Fick R, Rohane P, Effect of Severity of Disease on the Efficacy of Xolair – Results from Two Double-Blind, Placebo-Controlled Studies, Ann. Allergy Asthma Immunol. 86 No. 1, 82, 2001
  • Busse W, Corren J, Lanier BQ, Everhard F, Surrey K, Kirchdorfer L, Omalizumab Improves Asthma-specific Quality Of Life (QoL): An Analysis Of Data From 1071 Patients (abstract AAAAI February 2001)
  • Busse W, Corren J, Lanier BQ, Lee T, Nayak A, Chervinsky P, Gibson E, Fick R, Fowler-Taylor A, Gupta N, RhuMab-E25 (E25), a Novel Therapy for the Treatment of Allergic Asthma (AA) , Allergy Clin. Immunol. 105, No. 6, Pt. 1, 1246, 2000
  • Nayak A, Lanier BQ, Weinstein S,  Welch M, Stampone Beclomethasone dipropionate extrafine aerosol is safe and effective in childhood asthma: a 12-week, randomized, double-blind, placebo-controlled study - Submitted for publication

 

 

  • Abelson MB, Lanier BQ, The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Acta Ophthalmol Scand Suppl 1999;(228):53-6
  • Ableson MB, Lanier BQ, Evaluation of Patenol and Claritin for Allergic Conjunctivitis using the Conjuctival Antigen Challenge, Ann. Allergy Asthma Immunol. 82, No. 1, 90, 1999
  • Kelsen SG, Lanier BQ, et al; Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

            (J Asthma, 1999 Dec)

  • Raphael GD, Lanier BQ, et al; A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. (J Allergy Clin Immunol, 1999 May,
  • Nayak AS, Lanier BQ et al; The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. (J Allergy Clin Immunol, 1998 Feb,)
  • Rickard KA, Kelsen SG, Lanier BQ, Murray JJ, Emmett AH, Anderson WH, Church NL,  A Six Month Comparison of Adding Salmeterol to Doubling the Dose of Beclomethasone (BDP) in Asthma Patients with Symptoms on Inhaled Corticosteriods, Allergy Clin. Immunol. 101, No 1, Pt. 2, S232, 1998
  • Lanier,BQ  Multi-media intervention in numerous emergency room admissions Abstract presented to the American College of Allergy, Asthma, and Clinical Immunology, November 1998
  • A. Nayak, M.D., G. Feiss, M.S., J.A. Furst, B.S., B. Simpson, B.S., J.A. Smith, M.D., Easton, P.A., Abstract:  Triamcinolone Acetonide Aqueous Nasal Spray Does Not Alter Adrenocortical Function in Children With Allergic Rhinitis - American Academy of Allergy Asthma and Immunology Annual Meeting, New Orleans 1996.
  • Lanier, BQ, Sanders, N, The Effect of Asthma Support Groups on Patient Behavior, Abstract presented to the American College of Allergy, Asthma, and Clinical Immunology, November 1995
  • Szefler, SJ,  Lanier BQ, et al Evolving Role of Theophylline for Treatment of Chronic Childhood Asthma, Journal of Pediatrics, Vol 127, number 2,  pgs 176-185, August 1995
  • Lanier BQ; Confessions of an AMA rookie. (W V Med J, 1993 May)
  • Schuller D, Bellanti JA, Lanier BQ, Oconnell EJ, Scanlon R, Selner JC, Sparks DB, Storms W, One Organization or 2 0 The Cases For 2 Cooperative, Independent Societies Versus Reorganization Into One Society, Annals of Allergy, 1993, v70, n5 (May) p369-381
  • Zeitz HJ, Jamoszuk I, Lanier BQ, Storms WW, Greenstein S, Loratadine-Pseudoephedrine Combination vs. Clemastine Furnerate-Phenyl Propranolamine Combination in the Treatment of Seasonal Allergic Rhinitis, Eur. J. Allergy Clin. Immunol. 47, Suppl. 12, 103, 1992
  • Lanier, B.Q.:  Symposium on Pediatric Asthma, Who's Dying of Asthma and Why., Pediatrics,  pgs.838-840, November 1989.
  • Grossman J, Lanier BQ et al; Loratadine-pseudoephedrine combination versus placebo in patients with seasonal allergic rhinitis. (Ann Allergy, 1989 Oct)
  • Grossman J, Schenkel EC, Bronsky E, Linzmayer J, Selner C, Lanier BQ, Moss BA, Double Blind Control Study of Loratadine L 5 Mg Plus Pseudoephedrine P 120 Mg Sch434 In Seasonal Allergic Rhinitis, Sar Ann. Allergy 58 (4), 1987, 280
  • Rohr AS, Siegel SC, Katz RM, Rachelefsky GS, Spector SL, Lanier BQ, A Comparison of Inhaled Albuterol and Cromolyn in the Prophylaxis of Exercise-Induced Bronchospasm,  Annals of Allergy, Volume 59, August, 1987.
  • Rohr AS, Siegel SC, Katz RM, Rachelefsky GS, Spector SL, Lanier BQ, A Comparison of Inhaled Albuterol and Cromolyn in the Prophylaxis of Exercise-Induced Bronchospasm, J. Allergy Clin. Immunol. 77, No. 1, Pt. 2, 163, 1986
  • Lanier BQ, Tremblay N, Smith JP, DeFaller JM, A double-masked comparison of ocular decongestants as therapy for allergic conjunctivitis. (Ann Allergy, 1983 Mar)
  • Adinoff A, Tellez P, Lanier BQ, Fluorocarbon Propellants and Central Nervous System Stimulation in Asthma, Pediatrics, Sept. 1983, 82 (3) p438-9
  • Busy WW, Felman R., Lanier B., Malbeaux F.J., Munzenberger P., Papaianou H., Rowe M.S., Selner J.C., Seltzer J.M., Taylor W.H., White W.T., Terzian E., Mendols J., Ban AS A., "A two week multi-center double blind dose ranging study of the comparative efficacy and safety of low-dose sustained released Benedryl, standard released Benedryl and placebo in out patients with seasonal allergic rhinitis."  (Protocol 184-56-12-11)
  • Smith JP, Lanier BQ et al; Treatment of allergic conjunctivitis with ocular decongestants. (Curr Eye Res, 1982)
  • Jacobs RL, Lanier BQ, et al; Adverse reactions to tetanus toxoid, JAMA (The Journal of the American Medical Association), 1982 Jan, 247 (1) p40-2
  • Lanier BQ, Goldman AS, Harris NS, Bone Marrow Derived and Thymus Derived Lymphocytes in Dys Gamma Molecular Approaches to Immunology, Vol. 9, 1975
  • Lanier, B.:  Meat Tenderizer and Stings. Pediatrics, Vol. 69: 505-6, 1982.
  • Rossof, A.H., Lanier, B.:  Lithium Carbonate Therapy of the Shwachman Syndrome.  The Pediatric Bulletin, Mt. Sinai Hospital Medical Center of Chicago, Vol. 1, No. 2, April, 1981.
  • Lanier, Bobby:  An Approach to the Medical Management of Chronic Mouthbreathing (chapter).  Moyer's Symposium, Monograph No. 8, Craniofacial Growth Series, Center for Human Growth and Development, University of Michigan, Ann Arbor, Michigan, February, 1979.
  • Nichols, M.D., Lanier, B.Q., and Goldman, A.S.:  Cystic Fibrosis of the Pancreas in Black Infants with Absence of the Vas Deferens.  The Black Bag, Vol. 4, No. 1, March, 1975.
  • Lanier, B.Q., Goldman, A.S., and Harris, N.A.:  Plasma Cell Antigen on the Surface of Lymphocytes in Immunodeficient Patients (Abstract).  Presented to the Annual Meeting of the Reticuloendothelial Society, 1974.
  • Lanier, B.Q., Daeschner, C.W.:  Serious Complications of Suprapubic Aspiration of the Urinary Bladder. J. Pediat., 79: 711, 1971.
  • Lanier, B.Q., Nghiem, Q.X., and Derick, J.R.:  Prolonged Partial Bypass for Correction of Recurrent Coarction of the Aorta in a Patient with Unilateral Renal Agenesis.  Texas Medicine, 67:  99-100, 1971.

 

 

 

 

 

 

 

----------------------------------------------  non cited -------------------------------------

 

  • Lanier, B.Q.:  "Apathy", Medical Portfolio, Fall 1989.
  • Lanier, B.Q.:  A Matter of Opinion "A National Disgrace", Tarrant County Physician, February 1989.
  • Lanier, B.Q.: "Doctors and Unions", Medical Portfolio Volume 8, No. 2, July 1988.
  • Lanier, B.Q.: "Homeless" Cortlandt Group, 1988.
  • Lanier, B.Q.: "Malpractice and Lawyers", Medical Portfolio, Volume 7, No. 1 1988
  • Lanier, B.Q.: "Malpractice Prevention", Medical Portfolio Volume 6, No. 3 1987.
  • Lanier, B.Q.:  "Lawyer Bashing", Medical Portfolio, Vol. 7, No. 3, Sept.1987.
  • Lanier, B.Q.:  "The New Charlatans", RTNDA Communicator, Fall 1987.
  • Lanier, B.Q.: A Matter of Opinion "Affluenza" and the Millitant Patient Syndrome, Tarrant County Physician,  March 1986.
  • Lanier, B.Q.:  A Matter of Opinion "Where Did We Go Wrong?"  Tarrant County Physician, May 1985.
  • Lanier, B.Q.:  "Get to Know Your Patients Before You Meet Them".  Medical Economics, Pg. 121-122, Nov. 1985.
  • Lanier, B.Q.: "Media Polls and HMO's", Medical Portfolio, Vol. 6, No. 1, Sept. 1985.
  • Lanier, B.Q.: "Hospitals and Ambulatory Medicine". Editorial, Medical Portfolio, Vol. 5, No.3, Sept. 1984.
  • Lanier, B.Q.: "Patients Have a Ball With My Computer - And Learn a  Lot, Too".  Medical Economics, Pg. 189-197, March, 1984.
  • Lanier, B.Q.:  A Second Opinion (commentary). Medical Portfolio, Vol. 4, No.2, October, 1983
  • Lanier, B.Q.: "Pitfalls of the Diagnosis Related Group Concept". Editorial, Medical Portfolio, Vol. 3, No. 2, October, 1983
  • Lanier, Bobby:  Sex Education - Minority Report - Tarrant County Physician, Vol. 54, No. 5, September, 1982
  • Lanier, Bobby:  Editorial.  Physicians and the Pharmaceutical Industry, JAMA, September 10, 1982
  • Lanier, Bobby:  Of Physicians and Technology (Editorial). Medical Portfolio for Allergists, Vol. 2, No. 2, September 1981.

 

RESEARCH PROJECTS

·         AstraZeneca  D5360C00703 – Study to Assess the Safety and Efficacy of Rhinocort Aqua in patients 2-5 with AR

·         Criterium MGP707- A Multi-center, Three Arm, Parallel group, Double-blind Placebo-controlled, randomized study of Bioequivalence and Efficacy of Fluticasone Propionate Nasal Spray Compared to Flonase Nasal Spray In Patients with Seasonal Allergic Rhinitis

·         Schering PO4095 – Efficacy and Safety of Combination Loraradine/Monelukast QD vs Pseudoephedrine and Placebo in the Treatment of Subjects with Seasonal Allergic rhinitis

·         Alcon C-03-49 – Olopatadine VRS Astelin in patients with allergic rhinitis

·         Symbio CPL-404 – Triamcinolone Acetonide Nasal Spray compared with Nasacort AQ

·         Alcon C-04-20 – Peds Study, Olopatadine Hydrochloride Nasal Spray versus Placebo

·         Altana Pharma BY90101/M1-403  - Study to Assess the Safety and Efficacy of Ciclesonide Nasal Spray vs. Placebo in Children 6 - 11 with PAR.

·         ALTANA Pharma BY217/M2-023 – Roflumilast versus Placebo

·         AstraZeneca D5896C0005 – Symbicort versus Advair

·         Alcon C-01-92 – Long Term Safety Study of Olopatadine Nasal Spray

·         AstraZeneca SD-004-0764 – Comparing the Efficacy and Safety of Pulmicort Respules at different dosages and the Pulmicort Turbuhaler in patients ages 12 years and older with moderate to severe asthma.

·         AstraZeneca SD-004-0726 – Comparison of Pulmicort Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Children and Adolescents.

·         ALTANA Pharma BY9010/M1-402 – Study to Assess the Safety and Efficacy of Ciclesonide Nasal Spray vs. Placebo in Patients 12 and Older with PAR.

·         Dey D1-055 – Pediatric Study comparing Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler; placebo controlled.

·         Sepracor 051-354 – An Efficacy, Safety, and Tolerability Study of daily dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects (4-11 years) with Asthma.

·         Aventis MO16455P/3001- Study to assess the efficacy and safety of Fexofenadine with subjects with mild to moderate persistent asthma.

·         Aventis MO16455P/3003 – Study to assess the long-term safety performance of Fexofenadine compared to Montelukast.

·         Aventis XRG5029C/4007 – Comparing the Efficacy of Nasacort AZ with Rhinocort for the Treatment of Seasonal Allergic Rhinitis Symptoms in patients 12-65 years of age.

·         Novartis CFOR258D2307 – Evaluating safety and efficacy of treatment with 24 mcg bid and 12 mcg bid formoterol, and 12 mcg bid formoterol with additional on-demand doses in adolescent and adult patients with persistent stable asthma.

·         Astra Zeneca SD-039-0718 – Symbicort versus its Mono-Products (budesonide and formoterol) in Asthmatic Children Aged 6 – 15 yrs.

·         Astra Zeneca SD-004-0620 Comparison of Pulmicort Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults

·         Sepracor 051-353 – Efficacy and Safety Study of Levalbuterol, Racemic Albuterol in subjects 12 years and older.

·         Aventis XRP1526B-341 – Ciclesonide Metered Dose Inhaler in the treatment of children with persistent asthma.

·         GlaxoSmithKline SAS40036 – Comparison of Asthma Control in adolescents and adults receiving either Fluticasone Propionate/Salmeterol Diskus combination product, Fluticasone Propionate Diskus, Salmeterol Xinafoate Diskus, or Oral Montelukast.

·         Aventis HMR3647A/3014 – Oral Telithromycin and Amoxicillin/Clavulanic Acid in outpatients with respiratory tract infections in usual care settings.

·         Novartis FOR258F0604 – Evaluating the safety, efficacy, and pharmacokinetics of Foradil versus placebo.

·         Sepracor 110-073 – A Double-Blind, Placebo and Active-Controlled, Parallel Group Study of Tecastemezole.

·         Schering-Plough PO1861 – A Placebo and Active Controlled Efficacy and Safety Study of Desloratadine/Pseudoephedrine.

·         Genentech, Inc. Q2461g – An open-label study II of  of Omalizumab in moderate to severe, persistent asthma subjects.

·         Genentech, Inc. Q2195g – An open-label extension study of Omalizumab in moderate to severe, persistent asthma subjects.

 

·         Genentech, Inc. Q2143g – An open label study to evaluate the safety of Omalizumab in moderate to severe, persistent asthma subjects.

·         Schering  S83-022  - A Comparison of Two Major Treatment Modalities in the Therapy of Exercise Induced Asthma

·         Schering  S85-035  - A Study of the Safety and Efficacy of Loratadine Plus Pseudoephedrine Compared with Placebo in Patients with Seasonal Allergic Rhinitis

·         Schering  S87-001 SCH 434 - Loratadine Plus Pseudoephedrine) Versus Tavist-D in Seasonal Allergic Rhinitis

·         Warner-Lambert/Parke-Davis 184-56 - A Two-Week, Multicenter, Double-Blind, Dose-Ranging Study of  the Comparative Efficacy and Safety of Low Dose Sustained Release Benadryl, Standard-Release Benadryl, and Placebo in Outpatients with Allergic Rhinitis

·         Schering  S88-001 - Once Daily Claritin vs. Benadryl, Three Times Daily, Verses Placebo

·         Schering  S88-047-03 - Loratadine Tablets vs Loratadine Capsules vs Placebo in Seasonal Allergic  Rhinitis

·         Schering-Plough  C91-105-103  - A Patient Preference Study of Vanceril MDI vs Azmacort MDI

·         Parke-Davis  888-201 - A Multicenter Double-Blind Three Month Study of the Comparative Efficacy and Safety of Procaterol and Albuterol Aerosol Administered QID in Outpatients with Reversible Bronchial Airway Obstruction

·         Rhone-Poulenc Rorer 5016-117 - A Cohort Epidemiologic Study to Determine the Effect of One Year  of Azmacort (Triamcinolone Acetonide) or Alternate Day Prednisone or Alternate Day Prednisone Plus Azmacort or Nonsteroidal Antiasthmatic Therapy on Growth Patterns of Asthmatic Children

·         Glaxo  FLI-302 - A Randomized Double-Blind Comparative Trial of Inhaled Fluticasone Propionate Versus Theophylline Verses Placebo in  Adolescent and Adult Patients with Mild to Moderate Asthma

·         Carter Wallace 368 – A Randomized, Double-Blind Study of Astelin Nasal Spray versus Combination Therapy Nasal Steroid and Oral Antihistamines in Subjects with Seasonal Allergic Rhinitis.

·         Aventis MO16455C/3212 - A Double-blind, Randomized, Placebo-controlled, Parallel Group Study Assessing the Efficacy and Safety of Fexofenadine in Pediatric Subjects.

·         Aventis MO16455I/3112 – A Multicenter, Double-Blind, Randomized, Placebo-controlled. Parallel Study to Assess the Safety and Tolerability of Fexofenadinein Children  ages 2 through 5.

·         Aventis MO16455I/3112B A Multicenter, Double-Blind, Randomized, Placebo-controlled. Parallel Study to Assess the Safety and Tolerability of Fexofenadinein Children  ages 2 through 5.

·         Aventis MO16455P/2113 – A Multi-center, Doulbe-Blind, Randomized, Parallel Groups Placebo-controlled Pilot Study to Observe the Effects of Montelukast in combination with Fexofenadine on  Persistent Mild to Moderate Asthma Subjects.

·         Glaxo Wellcome FDP40012- A Randomized, Double-Blind, Double Dummy, Parallel Group Comparison of Fluticasone Inhalation Powder via Diskus with Oral Montelukast Chewable Tablets in Children ages 6-12 with Persistent Asthma.

·         GlaxoSmithKline SAM40027 – A Multicenter, Stratified, Randomized, Double-Blind, Parallel Group, Step-up Comparison of the Level of Asthma Control Achieved with Salmeterol/Fluticasone Combination Diskus compared with Fluticasone Diskus Alone in Adults and Adolescents.

·         Glaxo Wellcome SAS40026 – A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Combination Diskus Versus Fluticasone inhaler in Adolescents and Adults with Moderate Persistent Asthma

·         Glaxo Wellcome SAS40021 – A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12 Week Comparative Trial of Salmeteral/Fluticasone Combination Diskus Versus Oral Montelukast in Adolescents and Adults with Persistent Asthma.

·         Glaxo Wellcome FMS30058 – A Multicenter, Randomized, Doulbe-Blind, Parallel group, Placebo-controlled, 12 –week Study of Fluticasone Propionate Delivered CFC MDI and a Valved Holding Chamber with Facemask in Subjects Age 24 Months to 47 Months with Asthma.

·         Glaxo Wellcome FMS30059 - A Multicenter, Randomized, Doulbe-Blind, Parallel group, Placebo-controlled, 12 –week Study of Fluticasone Propionate Delivered CFC MDI and a Valved Holding Chamber with Facemask in Subjects Age 6 Months to 23 Months with Asthma.

·         Immunex 13.0019 – Phase II Efficacy Study of Nebulized Recombination Human IL-4 Receptor in Asthma Patients using Inhaled Corticosteriods.

·         Millennium M97700-023 – A Phase II, Randomized, Placebo-controlled, Double-Blind, Parallel group Dose-Finding Study to Evaluate the Effectiveness of Treatment with LDP-977 in Adult Asthmatics.

·         Amyllin 137-122  - A Double-Blind, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide in Patients with Type II Diabetes Mellitus.

·         Alcon C-99-37 – A Randomized, Controlled Study to Evaluate the Safety and Efficacy of Topical Cipro Compared to Cortisporin for treatment of Acute Otis Externa.

·         Alcon C-00-33 – A Placebo-controlled, Environmental Study of Patanol Nasal Spray versus Astelin Nasal Spray in Subjects with Seasonal Allergic Rhinitis.

·         Whitehall Robins AD-99-02 – Advil Multi-Symptom Allergy Sinus Efficacy and Safety Study

·         3M 1343-BRON – A 12-week Comparison of Daily Dose of Beclomethesone Dipropionate versus Placebo in Autohaler Device in Pediatric Patients with Symptomatic Asthma.

·         3M 1332-SILV – Safety and Efficacy Study of Albuterol Sulfate Delivered from a Press and Breath MDI, the Autohaler and Placebo in Patients with Asthma.

·         Sepracor 091-004 – A Safety, Efficacy and Tolerability Study of Multiple Once-Daily Doses of  Fometerol Inhalation Solution in Subjects with Asthma.

·         Schering Plough PO1998-21- Efficacy and Safety of Combination Loratadine/Monelukast versus Its Components in the Treatment of Subjects Seasonal Allergic Rhinitis.

·         Schering Plough PO1545-16 – Placebo-controlled Efficacy and Safety Study of a Once- Daily and Twice-Daily Regimens of Mometasone Furoate via Dry Powder Inhaler in Subjects with Asthma Previously Maintained on Inhaled Corticosteroids.

·         Schering Plough PO00687-09 – Efficacy and Safety of SCH29851 in Subjects with Seasonal Allergic Rhinitis.

·         Schering Plough PO0216-27 – Efficacy and Safety of SCH34117 in Patients with Seasonal Allergic Rhinitis and Concurrent Asthma.

·         Rhone-Poulenc Rorer RG5016Y-204 – A Phase II/III Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Efficacy, Safety and Dose Response Study of Azmacort Inhalation Aerosol in treatment of Mild and Moderate Persistent Asthma in Adolescents and Adults.

·         Pfizer A3771001 – A Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Cetrizine-Pseudoephedrine versus Loratadine-Pseutophedrine versus Placebo in the Treatment of Subjects 12 and Older with Seasonal Allergic Rhinitis.

·         G.H. Besselaar Associates  GHBA-168 - (Astra Draco  04-3022) A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy and Safety of Three Different Doses of Pulmicort (Budesonide) Turbuhaler in Pediatric

      Patients with Glucocorticosteroid Treated Asthma

·         Glaxo SLGA 5003 - A Randomized, Double-Blind, Parallel Group Evaluation of the

       Safety, Efficacy, and Effect on Asthma Quality of Life of Salmeterol Versus

       Albuterol in Inhaled Corticosteroid-Free and Inhaled Corticosteroid-Treated

       Asthma Subjects

·         Astra USA  04-3072 - A Study of Three Dose Levels of Budesonide (Pulmicort)

      Nebulizing Suspension and Placebo in Asthmatic Children Aged Between Four

      and Eight Years

·         Merck  MK-0476 - A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Clinical Effect of Three Oral Doses of MK-0476 and Placebo in Adult

       Patients with Stable, Moderate Asthma

·         Rhone-Poulenc Rorer RG-5016T-203 - A Double-Blind, Dose-Ranging Study of

      Azmacort HFA-134a Oral Inhaler Compared to Azmacort Oral Inhaler in the

Treatment of Asthma in Children

·         Glaxo SLGA5017 - A Comparison of Adding Serevent Versus Doubling the

      Dose of Beclovent in Asthmatic Subjects Symptomatic on Their Existing

      Inhaled Corticosteroids

·         Glaxo FLTA2008  - A Randomized, Double-Blind, Parallel-Group Trial Assessing the

      Efficacy and Safety of Fluticasone Propionate via the Multi-Dose Powder

      Inhaler 100MCG BID, 200 MCG QD, and Placebo in Subjects Aged 4 to 11

      Years with Chronic Asthma

·         SmithKline Beecham Pharmaceuticals SB 205312/012 -A Multi-Center,

      Double-Blind, Placebo-Controlled, Parallel Group Comparison of the Safety

      and Efficacy of Oral Twice Daily Administration of SB 205312 with Inhaled

      Tilade in Patients with Mild to Moderate Asthma

·         Rhone-Poulenc Rorer RG5029Y  A Randomized, Placebo-controlled, Parallel Group,

      Multiple-Dose Study of RG5029Y on Hypothalamic-Pituitary-Adrenal (HPA)

      Function and Pharmacokinetic Profile in Pediatric Patients with Allergic Rhinitis

·         SmithKline Beecham Pharmaceuticals SB 205312-084  A Multi-Center,

      Double-Blind, Placebo-Controlled, Parallel Group Study of Evaluate the Safety

      and Efficacy of Oral Twice Daily Administration of SB 205312 in Pediatric Patients

      with Mild to Moderate Asthma

·         Glaxo FLTA2006  A Randomized, Double-Blind, Double Dummy,

Parallel-Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate 50 or 100 mcg BID Via the Multi-Dose Powder Inhaler, Fluticasone Propionate 50 or 100 mcg BID Via the Diskhaler and Placebo in Subjects Aged 4 to 11 Years with

      Chronic Asthma

·         SmithKline Beecham Pharmaceuticals SB 205312-087  A Multi-Center, Open Label, Long Term Study of the Safety, Tolerability and Efficacy of Oral SB 205312 in Pediatric Patients with Mild to Moderate Asthma

 

·         Glaxo Wellcome FLTA4015  A Randomized, Double-Blind, Parallel-Group, Comparative Trial of inhaled Fluticasone Propionate (84 mcg and 336 mcg BID) Via the Metered-Dose Inhaler in Asthmatic Subjects Previously Treated with Beclomethasone Dipropionate

·         Hoechst Marion Roussel PJPR0053  A Double-Blind, Randomized Study Comparing the Efficacy and Safety of Fexafenadine and Placebo in Black Patients with Seasonal Allergic Rhinitis

·         TAP Pharmaceuticals M94-216  Safety and Efficacy of AA-2414 (ABT-001) in Patients with Moderate Asthma

·         SmithKline Beecham Pharmaceuticals SB 205312-080  A double-blind, double dummy, placebo-controlled, randomized, parallel group study to examine the effects of oral SB 205312 mg BID in patients with asthma and concomitant seasonal allergic rhinitis - a comparison to patients taking inhaled Vanceril 168 mcg BID and as required nasal rescue medication

·         Sepracor 051-024  A Phase III Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of the effects of (R)-Albuterol in the Reversal of Bronchoconstriction and in the Management of Asthma

·         SmithKline Beecham Pharmaceuticals SB 205312-07 A Multicenter, Double-blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Two Doses Of SB 205312 Administered As An Oral Suspension (75 MG BID And 150 MB BID) for 12 Weeks In Pediatric Out-Patients With Asthma

·         Glaxo Wellcome  SLGA 5021  A Randomized, Double-blind Clinical Trial Comparing The Efficacy And Safety Of Salmeterol Xinafoate 42 MCG BID Plus Fluticasone Propionate 88 MCG BID Alone In Subjects with Asthma Not Well controlled On Fluticasone Propionate 88 MCG BID

·         Ciba-Geigy Corporation  51901 01 04  A Double-blind, Randomized, Parallel-Group, placebo-Controlled, Multiple-Dose (Intravenous Infusions of 35 MG, 58 MG, or 93 MG CGP 51901 Q 2 Weeks x 6) Multicenter Pilot Trial To Assess The Efficacy, Safety, Tolerability, Pharmacokinetics, And Biologic Activity of CGP 51901 In Patients 18-40 Years Old With Mild To Moderate Perennial Allergic Asthma

·         GlaxoWellcome FLTA 4025   A Randomized, Double-Blind, Placebo-controlled Study Examining The Effect Of Fluticasone Propionate Aqueous Nasal Spray 200 MCG QD Used In Conjunction With An Antibiotic In Allergic Subjects With Recurrent Sinusitis

·         Novartis 049   A Twelve-month, Double-Blind, Between-Patient, Placebo-Controlled Trial Comparing the Safety, Tolerability and Efficacy of 12 ug and 24 ug and 24 ug Twice Daily Formoterol Dry Powder Capsules for Inhalation Delivered by a Single-Dose Inhaler (Aerolizer) in Children With Asthma in Need of Daily Treatment with Inhaled Bronchodilators and Anti-Inflammatory Treatment

·         Glaxo SFCA 3003   A Randomized, Double-Blind Trial Evaluating safety and Efficacy of Salmeterol 50 mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Patients with Asthma

·         Abbott M96-464   Long Term Safety Study of Zileuton Controlled-Release Plus Usual Care Versus Placebo Plus Usual Care in Patients with Asthma

 

 

 

 

 

 

·         Novartis Pharmaceuticals rhuMAb-E25 01 006 - A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose (Subcutaneous Administrations of 50 mg, 150, mg or 300 mg), Multicenter, Dose-Ranging Trial To Assess The Efficacy, Safety, Tolerability, Pharmacokinetics And Biological Effect Of Anti-Ige Recombinant Humanized Monoclonal Antibody-E25 (rhuMAb-E25) Versus Placebo For Symptoms Effect Of Anti IgE Recombinant Humanized Monclonal Antibody-E-25 (rhuMAb-E25) Versus Placebo For Symptom Prevention In Patients With Ragweed Induced Seasonal Allergic Rhinitis”

·         Astra Merck 153 - Comparison of the Safety and Antihypertensive Efficacy of the Fixed Combination of Candesartan Cilexetil and Hydrochlorothiazide (32/12.5 mg) Once Daily with the Individual Components Administered Once Daily: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Design Study

·         Pfizer L-0350, An open Label, Multicenter Study of the Efficacy, Safety, and effect on Quality of Life of Zyrtec® (certirizine HCL) Syrup in the Treatment of Seasonal Allergic Rhinitis in Children

·         Hoechst Marion Roussel MO16455B / 3081 - A Double-blind Randomized, Placebo-Controlled Parallel Study comparing the Efficacy and Safety of Fexofenadine HC1 120 mg And 180 mg QD In The Treatment Of Autumn Seasonal Allergic Rhinitis

·         Schering-PloughC97- 223-16 - Placebo-Controlled Efficacy and Safety Study with Long-Term Safety Evaluation of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists

·         Forest AER-MD-07-000   Aerobid -- Once-A-Day with AeroChamber in Mild to Moderage Asthma Patients

·         GlaxoWellcome FLTA 4030 - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate (88 mcg BID) Versus Zafirlukast (20mcg BID), in Subjects Who are Currently Receiving Beta Agonista Alone

·         Astra Merck 175 - Evaluation of the Antihypertensive Effect of Candesartan Cilexetil

in Comparison to Losartan

·         ViroPharma 843-013 - A Double-Blind, Placebo Controlled Exploratory Evaluation 

      of  Pleconaril (VP-63843) in the Treatment of Rhinovirus Upper Respiratory Tract

      Infections in Patients with Moderately Severe Bronchial Asthma

·         GlaxoWellcome FLTA 4035  - A Randomized, Double-Blind, Double-Dummy, Parallel Group, Comparative Study of Inhaled Fluticasone Propionate 88 Mcg BID Versus Zafirlukast 20 Mg BID in Asthmatic Subjects Who Are Currently Receiving Low Dose Inhaled Corticosteroids

·         Novartis Pharmaceuticals rhuMAb-E25 01 008 - A Phase III, 7 Month, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial With a 5-Month Blinded Extension Period To Assess the Efficacy, Safety, Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Adolescents and Adults With Moderate To Severe Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids

·         Wallace 368  - A Randomized, Double-Blind Study of Astelin® Nasal Spray Monotherapy Versus Combination Therapy of A Nasal Steroid and Oral Antihistamine in Subjects With Seasonal Allergic Rhinitis

·         Astra Merck Inc. 183 - A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Omeprazole, 10 mg QD,

      in Preventing Heartburn

·         Novartis Pharmaceuticals rhuMAb-E25 01 010 - A Phase III, 7 Month, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial With a 5-Month Open-Label Extension Period To Assess  Safety and Tolerability, Steroid-Reduction, Pharmac cokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 years) With Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids

·         Novartis Pharmaceuticals rhuMAb-E25 01 010 Extension- A Phase III, 7 Month, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial With a 5-Month Open-Label Extension Period To Assess  Safety and Tolerability, Steroid-Reduction, Pharmac cokinetics, and Pharmacodynamics of Subcutaneous rhuMAb-E25 in Children (6-12 years) With Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids

·         Alcon C98-19 - Topical CILODEX™ (ciprofloxacin 0.3%, dexamethasone 0.1%) Suspension Compared to CORTISPORIN® Suspension (neomycin 0.35%, ploymyxin, 10,000 IU mL, Hydrocortisone 1.0%) for Treatment of Patients with Acute Otitis Externa (AOE)

·         Alcon C98-04 - An Observer-Masked Adjunctive Therapy Environmental Study of Patanol With Claritin Versus Claritin Alone in Patients With Seasonal Allergic Conjunctivitis

·         Rhone-Poulenc Rorer 5016Y-204 - A Phase II/III Double Blind Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Azmacort (triamcinolone acetonide) HFA-134a Inhalation Aerosol 225 mcg, 450 mcg and

      900 mcg Administered Once Daily for 12 weeks in the Treatment of Mild Persistent

      and Moderate Persistent Asthma in 800 Adolescents and Adults

·         Novartis 009 - A Phase III, 7-Month, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Trial with a 5-Month Blinded Extension Period to Assess The Efficacy, Safety, Tolerability, Steroid-Reduction, Pharmacokinetics of Subcutaneous rhu-MAB-E25 in Adolescents and Adults With Moderate to Severe Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroids.

·         Pfizer 362 - A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Efficacy, Safety, and Effect on Quality of Live, Work Productivity and Activity Impairment of Zyrtec vs. (Cetirizine HCI)  vs. Placebo in the Treatment of Seasonal Allergic Rhinitis

·         FLTA 4038 - A Randomized, Double-Blind, Parallel Group Comparison Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD) in Subjects Currently Receiving Beta Agonists Alone

·         GlaxoWellcome 40004 - A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) With Oral Montelukast (10mg QD) In Subjects With Persistent Asthma Symptomatic on Concomitant Inhaled Corticosteroid Therapy

·         GlaxoWellcome 30004 - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of Salmeterol/Fluticasone Propionate Combination in GR106642X MDI, 50/250mcg BID, and Salmeterol in Propellant 11/12MDI, 50mcg BID, and Fluticasone Propionate in Propellant 11/12MDI, 250mcg BID, and Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma

 

ONGOING RESEARCH PROJECTS

 

·         Novartis CIGE025AUS23- A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center, Study to Evaluate the Effect of Xolair (Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients with Persistent Allergic Asthma

·         Alcon C-05-69: 12 month safety study of Olopatadine Nasal Spray

·         Schering Plough P04824-efficacy/safety of MFNS vs placebo as adjunctive treatment to antibiotics in relief of symptoms of acute bacterial sinusitis

·         Sanofi Aventis EFC6695-efficacy/safety of ciclesonide metered-dose inhaler at 80 mcg BID vs 40 mcg BID vs placebo in children 4 to 11 yrs

·         Sanofi Aventis  XRG5029C/3503-12 month effect of treatment with QD triamcinolone acetonide on growth velocity of children 3-8 yrs with SAR

·         Amgen Inc. AMG317-safety/efficacy of AMG317 in subjects with moderate to severe asthma

·         Genentech Q3663g – A Phase III Multicenter, randomized, Double-blind Placebo-controlled, study of Xolair in subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with Advair 500/50

·         Fujisawa FHI 03-0-161 / FG- 506-06-37- APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for Treatment of Topical Dermatitis

·         Novartis IGE025A US23-Omalizumab efficacy on improving tolerability of specific immunotherapy in patients with persistent allergic asthma

·         Genentech Q2948g – An Epidemiologic study of Xolair Evaluating Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma

·         Novatris CIGE025AIA05 – An Evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Omalzumab in Children 6-12 with Moderate-Severe Persistent Asthma